Tag Archives: Kite Pharma

CAR-T Therapy: Personalized medicine with the promise of a cure; payers will decide who gets it

The News: Swiss drug giant Novartis AG has drawn widespread praise and a rising dose of controversy pertaining to its breakthrough CAR-T therapy CTL019. The medicine is under review to… Read more »

Drugs that may shape 2017 and the trends molding new-drug discovery

Here’s a look at the drugs that may shape 2017, compliments of FirstWord Pharma. It’s a list of some of the products I agree are likely to dominate industry news… Read more »

Gilead starts 2017 by snatching Novartis cancer specialist; a harbinger of early (and ferocious) M&A?

Gilead Sciences Inc. (Foster City CA) has poached a top cancer specialist from Swiss drugmaker Novartis AG (Basel) as the US healthcare group sharpens its focus on oncology. Alessandro Riva… Read more »

Gilead loses record $2.5 billion patent verdict to Merck; so what’s a couple billion when you’ve got plenty more and need to grow–fast?

Gilead Sciences Inc. (Foster City CA) was told by a federal jury to pay $2.54 billion to Merck & Co. (Kenilworth NJ) for using a patented invention as the basis for its… Read more »